CN110325548B - 抗硬化蛋白抗体在治疗成骨不全症中的用途 - Google Patents

抗硬化蛋白抗体在治疗成骨不全症中的用途 Download PDF

Info

Publication number
CN110325548B
CN110325548B CN201780087087.2A CN201780087087A CN110325548B CN 110325548 B CN110325548 B CN 110325548B CN 201780087087 A CN201780087087 A CN 201780087087A CN 110325548 B CN110325548 B CN 110325548B
Authority
CN
China
Prior art keywords
ser
val
gly
thr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780087087.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN110325548A (zh
Inventor
U·容克
M·克奈塞尔
A·K·霍尔
R·J·尤迪
M·M·里格斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mereo Biopharma 3 Ltd
Original Assignee
Mereo Biopharma 3 Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mereo Biopharma 3 Ltd filed Critical Mereo Biopharma 3 Ltd
Priority to CN202311429543.0A priority Critical patent/CN117442720A/zh
Publication of CN110325548A publication Critical patent/CN110325548A/zh
Application granted granted Critical
Publication of CN110325548B publication Critical patent/CN110325548B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201780087087.2A 2016-12-21 2017-12-21 抗硬化蛋白抗体在治疗成骨不全症中的用途 Active CN110325548B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202311429543.0A CN117442720A (zh) 2016-12-21 2017-12-21 抗硬化蛋白抗体在治疗成骨不全症中的用途

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662437353P 2016-12-21 2016-12-21
US62/437,353 2016-12-21
PCT/GB2017/053850 WO2018115880A1 (en) 2016-12-21 2017-12-21 Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202311429543.0A Division CN117442720A (zh) 2016-12-21 2017-12-21 抗硬化蛋白抗体在治疗成骨不全症中的用途

Publications (2)

Publication Number Publication Date
CN110325548A CN110325548A (zh) 2019-10-11
CN110325548B true CN110325548B (zh) 2023-11-17

Family

ID=60915566

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201780087087.2A Active CN110325548B (zh) 2016-12-21 2017-12-21 抗硬化蛋白抗体在治疗成骨不全症中的用途
CN202311429543.0A Pending CN117442720A (zh) 2016-12-21 2017-12-21 抗硬化蛋白抗体在治疗成骨不全症中的用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202311429543.0A Pending CN117442720A (zh) 2016-12-21 2017-12-21 抗硬化蛋白抗体在治疗成骨不全症中的用途

Country Status (23)

Country Link
US (5) US20200179509A1 (https=)
EP (2) EP3478719B3 (https=)
JP (3) JP7050335B2 (https=)
KR (3) KR20190096409A (https=)
CN (2) CN110325548B (https=)
AU (1) AU2017381433B2 (https=)
BR (1) BR112019012731A2 (https=)
CA (1) CA3047221A1 (https=)
CL (1) CL2019001749A1 (https=)
CY (1) CY1124238T1 (https=)
DK (1) DK3478719T6 (https=)
ES (1) ES2862922T7 (https=)
FI (1) FI3478719T6 (https=)
HR (1) HRP20210207T4 (https=)
HU (1) HUE053436T2 (https=)
IL (1) IL267430B2 (https=)
LT (1) LT3478719T (https=)
MX (1) MX2019007161A (https=)
NZ (1) NZ754676A (https=)
PL (1) PL3478719T6 (https=)
PT (1) PT3478719T (https=)
SI (1) SI3478719T2 (https=)
WO (1) WO2018115880A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019007161A (es) * 2016-12-21 2020-02-12 Mereo Biopharma 3 Ltd Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
TWI795381B (zh) 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物
US10961305B2 (en) 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
EP3774879B1 (en) 2018-03-30 2026-01-28 Amgen Inc. C-terminal antibody variants
AU2019289222B2 (en) 2018-06-18 2023-07-13 Janssen Pharmaceutica Nv Pyrazole derivatives as MALT1 inhibitors
EP3953345B1 (en) 2019-04-11 2023-04-05 Janssen Pharmaceutica NV Pyridine rings containing derivatives as malt1 inhibitors
KR102472582B1 (ko) * 2020-08-20 2022-11-30 한림대학교 산학협력단 인공관절 마모편에 의한 활막염과 골용해의 진단 및 치료 방법
AU2022357544A1 (en) * 2021-09-30 2024-04-11 Mereo Biopharma 3 Limited Methods of using anti-sclerostin antibodies in treatment of osteogenesis imperfecta
WO2025212547A1 (en) * 2024-04-05 2025-10-09 Amgen Inc. Methods of treating osteogenesis imperfecta

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101646457A (zh) * 2007-03-20 2010-02-10 伊莱利利公司 抗硬骨素抗体
CN101821291A (zh) * 2007-10-12 2010-09-01 诺瓦提斯公司 抗硬骨素抗体的组合物和应用方法
TW201036650A (en) * 2009-03-05 2010-10-16 Novartis Ag Lyophilised antibody formulation
CN102844033A (zh) * 2010-04-16 2012-12-26 诺华有限公司 提高植入物骨结合的方法和组合物
WO2016092101A1 (en) * 2014-12-12 2016-06-16 Amgen Inc. Anti-sclerostin antibodies and their use to treat bone disorders as part of a regimen

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
ATE481487T1 (de) 1998-11-27 2010-10-15 Ucb Sa Zusammensetzungen und verfahren zur erhöhung der knochenmineralisierung
CA2529623A1 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
EP2423226A3 (en) 2006-11-10 2012-05-30 Amgen Inc. Antibody-based diagnostics and therapeutics
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
TWI452136B (zh) * 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
MX2019007161A (es) * 2016-12-21 2020-02-12 Mereo Biopharma 3 Ltd Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
US10961305B2 (en) * 2016-12-21 2021-03-30 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101646457A (zh) * 2007-03-20 2010-02-10 伊莱利利公司 抗硬骨素抗体
CN101821291A (zh) * 2007-10-12 2010-09-01 诺瓦提斯公司 抗硬骨素抗体的组合物和应用方法
EP2586796A1 (en) * 2007-10-12 2013-05-01 Novartis AG Compositions and methods for use for antibodies against sclerostin
TW201036650A (en) * 2009-03-05 2010-10-16 Novartis Ag Lyophilised antibody formulation
CN102844033A (zh) * 2010-04-16 2012-12-26 诺华有限公司 提高植入物骨结合的方法和组合物
WO2016092101A1 (en) * 2014-12-12 2016-06-16 Amgen Inc. Anti-sclerostin antibodies and their use to treat bone disorders as part of a regimen

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"sclerostin antibody therapy for the treatment of osteoporosis:clinical prospects and challenges;Claire MacNabb et al.;《J Osteoporos》;20160526;第1-22页 *
Andreas Roschger et al..effect of Sclerostin antibody treatment in a mouse model of severe Osteogenesis Imperfecta.《Bone》.2014,第66卷第182-188页. *
BPS804 ANTI- sclerostin ANTIBODY in adults with moderate osteogenesis imperfecta:results of a randomized phase 2a trial;Francis H Glorieux et al.;《J Bone Miner Res.》;20170329;第32卷(第07期);第1496-1504页 *
Claire MacNabb et al.."sclerostin antibody therapy for the treatment of osteoporosis:clinical prospects and challenges.《J Osteoporos》.2016,第1-22页. *
effect of Sclerostin antibody treatment in a mouse model of severe Osteogenesis Imperfecta;Andreas Roschger et al.;《Bone》;20140619;第66卷;第182-188页 *
Sclerostin Antibody Treatment Improves the Bone Pheno type of Crtap–/– Mice, a Model of Recessive Osteogenesis Imperfecta;Ingo Grafe et al.;《Journal of Bone and Mineral Research》;20160531;第31卷(第5期);第1030~1040页 *

Also Published As

Publication number Publication date
IL267430A (en) 2019-08-29
RU2019118719A3 (https=) 2021-06-01
CN117442720A (zh) 2024-01-26
AU2017381433B2 (en) 2024-11-14
EP3478719B3 (en) 2024-12-18
JP7050335B2 (ja) 2022-04-08
HRP20210207T1 (hr) 2021-03-19
IL267430B2 (en) 2026-01-01
LT3478719T (lt) 2021-04-12
RU2019118719A (ru) 2021-01-22
KR20220051269A (ko) 2022-04-26
AU2017381433A1 (en) 2019-07-04
CY1124238T1 (el) 2022-07-22
JP2022046529A (ja) 2022-03-23
MX2019007161A (es) 2020-02-12
US20210253684A1 (en) 2021-08-19
IL267430B1 (en) 2025-09-01
US20200123242A1 (en) 2020-04-23
US20200179509A1 (en) 2020-06-11
WO2018115880A1 (en) 2018-06-28
PL3478719T6 (pl) 2025-01-27
CA3047221A1 (en) 2018-06-28
FI3478719T6 (fi) 2025-01-20
HUE053436T2 (hu) 2021-06-28
EP3478719B1 (en) 2021-01-20
ES2862922T7 (en) 2025-02-26
CL2019001749A1 (es) 2019-12-27
KR20190096409A (ko) 2019-08-19
US20240400666A1 (en) 2024-12-05
HRP20210207T4 (hr) 2025-01-31
EP3478719A1 (en) 2019-05-08
JP2025020150A (ja) 2025-02-12
DK3478719T6 (da) 2025-01-20
ES2862922T3 (es) 2021-10-08
SI3478719T2 (sl) 2025-07-31
PL3478719T3 (pl) 2021-10-25
DK3478719T3 (da) 2021-03-01
PT3478719T (pt) 2021-03-18
US20230365669A1 (en) 2023-11-16
KR20240113615A (ko) 2024-07-22
JP2020502219A (ja) 2020-01-23
NZ754676A (en) 2023-06-30
SI3478719T1 (sl) 2021-09-30
BR112019012731A2 (pt) 2019-11-26
CN110325548A (zh) 2019-10-11
EP3868780A1 (en) 2021-08-25

Similar Documents

Publication Publication Date Title
CN110325548B (zh) 抗硬化蛋白抗体在治疗成骨不全症中的用途
AU2020340881B2 (en) Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments
CN110869389B (zh) 抗ror1抗体及其制备和使用方法
KR102361237B1 (ko) 코일드 코일 면역글로불린 융합 단백질 및 이것의 조성물
RU2750675C1 (ru) Антитела против pd-1 и композиции
KR101865974B1 (ko) β-ＫＬＯＴＨＯ, ＦＧＦ 수용체 및 이들의 복합체에 결합하는 인간 항원 결합 단백질
DK2586796T3 (en) Compositions and Methods for Using Antibodies against Sclerostin
KR101704893B1 (ko) Gdf-8에 대한 개선된 길항물질 항체 및 그의 용도
AU2015302959B2 (en) Anti-CDH6 antibody drug conjugates
KR20190104158A (ko) 위 저해 펩타이드 수용체(gipr)에 대한 길항제에 접합된 glp-1 수용체 작용제를 사용하여 대사 장애를 치료 또는 개선하는 방법
CN109311973A (zh) 含有c端融合的tnf家族配体三聚体的抗原结合分子
TW202400655A (zh) 使用胃抑肽受體(gipr)結合蛋白與glp-1促效劑之組合來治療或改善代謝病症之方法
CN107206072A (zh) T细胞活化性双特异性抗原结合分子CD3 ABD叶酸受体1(FolR1)和PD‑1轴结合拮抗剂的组合疗法
EA033369B1 (ru) Мутантные полипептиды интерлейкина-2 со сниженной аффинностью к высокоаффинному рецептору il-2 и неизменной аффинностью к рецептору il-2 с промежуточной аффинностью и их применение
KR20230017815A (ko) 항-sars-cov-2 스파이크 당단백질 항체 및 항원-결합 단편
KR20230027300A (ko) Il-10 뮤테인 및 이의 융합 단백질
KR20220002972A (ko) 변형 항 pd-l1 항체 및 신경변성 질환 치료 방법 및 용도
CN114096561A (zh) 使用交叉双重可变结构域(codv)形式用于治疗hiv感染的三特异性和/或三价结合蛋白
CN108570106B (zh) 抗埃博拉病毒单克隆抗体、其制备方法及用途
RU2789033C2 (ru) Применение антител к склеростину для лечения несовершенного остеогенеза
CN115666639A (zh) 用于防止治疗性蛋白吸附到药物递送系统部件的方法和组合物
RU2840013C1 (ru) Способ получения конъюгата антитело-лекарственное средство на основе эрибулина
HK40058067B (zh) 抗埃博拉病毒单克隆抗体、其制备方法及用途
EA044746B1 (ru) АНТИТЕЛА И АНТИГЕНСВЯЗЫВАЮЩИЕ ФРАГМЕНТЫ ПРОТИВ ГЛИКОПРОТЕИНА ШИПОВ SARS-CoV-2
KR20200018643A (ko) 면역 혈소판감소증의 치료 방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant